NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
Clinical Trials
41 trialsNCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT04407741 2023-12-12
Phase â… /â…¡ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05390528 2023-08-08
HLX301
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT02825836 2023-07-13
Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Telios Pharma, Inc.
Phase 1/2 Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT05400876 2023-02-14
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05654038 2022-12-21
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05651100 2022-12-14
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown
NCT02678299 2022-08-04
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
University of Aarhus
Phase 1/2 Unknown
NCT03789617 2022-07-11
A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies
Eutilex
Phase 1/2 Unknown
NCT04764513 2022-03-28
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT04458389 2021-08-13
A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas
Tayu Huaxia Biotech Medical Group Co., Ltd.
Phase 1/2 Unknown
NCT04762485 2021-06-02
Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
The First Affiliated Hospital of Soochow University
Phase 1/2 Unknown
NCT04873440 2021-05-05
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT03262298 2021-02-09
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT04427449 2020-06-11
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT04163575 2019-12-23
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Kecellitics Biotech Company Ltd
Phase 1/2 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT02349698 2019-06-25
A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Southwest Hospital, China
Phase 1/2 Unknown
NCT02935153 2019-06-25
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT02954445 2019-06-25
A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT02958410 2019-06-25
A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
Southwest Hospital, China
Phase 1/2 Unknown
NCT03312205 2019-01-09
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1/2 Unknown
NCT03468153 2018-03-20
Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
Ruijin Hospital
Phase 1/2 Unknown
NCT02488382 2017-10-17
Lonquek for Autologous Stem Cell Mobilization
Sheba Medical Center
Phase 1/2 Unknown
NCT03191773 2017-06-20
A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Unknown
NCT03118180 2017-04-18
CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Zhejiang University
Phase 1/2 Unknown
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT02274584 2014-10-24
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Peking University
Phase 1/2 Unknown
NCT00007839 2013-12-18
Beta Alethine in Treating Patients With Low-Grade Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00041379 2013-12-18
Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01983761 2013-11-18
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Targazyme, Inc.
Phase 1/2 Unknown
NCT00032149 2013-09-20
Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00363090 2013-09-20
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT01728389 2013-07-24
Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 1/2 Unknown
NCT00397800 2012-08-28
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Technical University of Munich
Phase 1/2 Unknown